GI CONNECT
@giconnectInfo
Followers
2K
Following
521
Media
436
Statuses
1K
COR2ED brings you Independent Medical Education developed by GI CONNECT, international experts in GI oncology. https://t.co/CePZ1NKOt9
Joined July 2015
Our Friends at @COR2EDMedEd bring you expert insights on the peri-operative use of immunotherapy in gastric and gastroesophageal junction cancers. Watch Here👉 https://t.co/QCI7gbzBb2
@KlempnerSam explores the current treatment landscape, the latest trial data, clinical
0
5
6
Get expert insights on the peri-operative use of #immunotherapy in gastric and GEJ cancer 📺 A #MedEd video from Assoc. Prof. Sam Klempner @KlempnerSam 🤝 Endorsed by @WarOnCancer, Esophageal Cancer Action Network & @StoCANcer See more & view/download the accompanying slides:
0
0
0
🚨 New on-demand resources! 🚨 Expert insights from the latest gastric and gastroesophageal cancer data from ESMO 2025 📺 Newly-released video & slides from a virtual Experts Knowledge Share Meeting Chair: Dr @LizzySmyth1 (UK) Co-Chairs: Prof. Aziz Zaanan (France) & Prof.
0
1
1
📣 New GI oncology video! ‘Peri-operative use of immunotherapy in gastric and GEJ cancer’ 📺 >> From Assoc. Prof. Sam Klempner (@KlempnerSam) Get expert insights on: -the current treatment landscape -latest trial data -clinical impact & safety considerations and more! See
0
0
0
Liquid biopsy offers a novel, non-invasive testing method to determine the molecular profile and suitability for rechallenge in mCRC But how do you know when to switch to another therapy? Prof. @andrea_sart takes you through a patient case video 📺 Learn about: - Later-line
3
25
118
‘Peri-operative use of immunotherapy in gastric and GEJ cancer’ 📺 A new educational video from Assoc. Prof. Sam Klempner - @KlempnerSam Get expert insights on the current treatment landscape, latest trial data, clinical impact, safety considerations, and more >> Endorsed by
1
2
5
‘Peri-operative use of immunotherapy in gastric and GEJ cancer’ 📺 A new educational video from Assoc. Prof. Sam Klempner (@KlempnerSam) Get expert insights on the current treatment landscape, latest trial data, clinical impact, safety considerations, and more >> Endorsed by
0
0
1
Expert insights on the LEVIATHAN publication >> Evaluating lenvatinib versus sorafenib as 2nd line treatment post atezolizumab plus bevacizumab for HCC 📺 Prof. David Pinato (@DJPinato) discusses key findings & implications for practice View the infographic:
0
0
1
Important discussion on current and emerging approaches in #NeuroendocrineTumours, featuring expert perspectives on radioligand therapy and clinical practice. Here’s the highlights presented by @net_connectinfo and @giconnectInfo, with experts moderated by the @OncBrothers
Dr @helops79, @ProfKHerrmann & @OncBrothers share their perspectives on advances in the management of #neuroendocrine tumours Spotlight on the role of radioligand therapy and its impact on clinical practice 🔦 📹 Video in this post 🤝 Endorsed by @NANETS1, CommNETs
0
0
4
🚨 Final call! 🚨 Sign up for the virtual Experts Knowledge Share to discuss gastric/gastroesophageal cancer data from #ESMO25 How will new data impact clinical practice? >> 19th November >> 17:00 -18:15 CET / 11:00 -12:15 EST Topics: - Future of targeted therapy & IO -
0
0
0
➡️ Liquid biopsy offers a novel, non-invasive testing method to determine the molecular profile and suitability for rechallenge in mCRC But how do you know when to switch to another therapy? Prof. @andrea_sart takes you through a patient case video📺 Learn about: - Later-line
0
0
1
📢 Raising awareness for #WorldNeuroendocrineCancerDay! Understanding EP-NEC: Through diagnosis, treatment, and support >> What do the differences between NETs and NECs mean for patients? Poorly differentiated, high-grade, aggressive cancers need urgent treatment options. Find
0
0
3
Experts discuss gastric/gastroesophageal cancer data from ESMO 2025 and ask: what are the implications for clinical practice? Don’t miss out - sign up for the interactive webinar now! 19th November 17:00 -18:15 CET / 11:00 -12:15 EST >> Secure your place:
0
1
2
Virtual Experts Knowledge Share, sign up now! Join your peers to discuss new gastric and gastroesophageal cancer data from #ESMO25 & insights for clinical practice 🗓️ 19th November ⏰ 17:00 -18:15 CET / 11:00 -12:15 EST 🔗Secure your place: https://t.co/yLQwdEedlP Topics: -
0
0
4
Upcoming webinar from @ESDO_tweets New Data on GI Cancer at ESMO 2025: Integration in Treatment Algorithms >> Moderated by Eric Van Cutsem & Pieter-Jan Cuyle 🔸Colorectal Cancer - Thomas Seufferlein, Ulm, Germany 🔸Hepatocellular Carcinoma - Piotr Wysocki, Gdansk, Poland
0
0
6
1st ESDO Live Webinar: 6 Nov 2025 / 20:00 - 21:30 New data on GI cancer at ESMO 2025: integration in treatment algorithms #ESMO2025 #ESMO25 Gain first-hand insights and engage with thought leaders in the field. REGISTRATION https://t.co/S3zvhnIZrP
0
2
7